• Text size      
  • Send this article to a friend
  • Print this article

Scots cancer patients denied drug used in England

A DRUG which extends the lives of patients who are dying from skin cancer has been approved for use on the NHS in England – but rejected in Scotland.

The National Institute for Health and Clinical Excellence has backed the use of Zelboraf in appropriate melanona patients, two months after it was turned down by the Scottish Medicines Consortium (SMC).

Charities, cancer clinicians and drugs companies have all raised concern that patients north of the Border are increasingly unable to access new treatments which are prescribed in England and Wales.

John Melville, managing director of pharmaceutical company Roche UK, said: "While this is a landmark for metastatic melanoma patients in England and Wales, this reinforces the urgency for the SMC to review the criteria it uses to assess cancer medicines to help prevent Scotland falling further behind."

A spokesman for SMC said: "We were disappointed not to be able to recommend this medicine ."

Contextual targeting label: 

Commenting & Moderation

We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis.
If you're a relatively new user then your comments will be reviewed before publication and if we know you well and trust you then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules

Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.